Ayman Hassan

Ayman Hassan

Vice President and UAE General Manager at Novo Nordisk


To shed more light on Novo Nordisk specific activities we had an interview with Dr. Ayman Hassan, Vice President and UAE General Manager at Novo Nordisk.

First,  I have to commend the business environment in the UAE and the authorities have put a great effort in attracting global business into UAE through supportive laws and regulations which, as evident to everyone, has paid off significantly. On the other hand, Novo Nordisk is one of the fastest growing multinational pharmaceutical companies in the UAE in 2017. This was primarily driven by the introduction of new medicines that added value to the well-being of patients and addressed their unmet needs together with the strong local focus and investments.

Diabetes and obesity are big health challenges with almost one fifth of the population being affected by diabetes and one third being affected by obesity. On the obesity front, we plan to collaborate with the Health Authorities to develop stronger knowhow about managing obesity, increase awareness towards the issue and ensure that the best management options are available. While on the diabetes front, several activities were conducted focusing on raising awareness towards diabetes through team Novo Nordisk (the world’s first all-diabetes professional cycling team, which participated in the Dubai Tour, with the mission to inspire, educate and empower everyone affected by diabetes. We also supported many academic and educational activities in collaboration with international Universities, Dubai Health Authority, Ministry of Health and Health Authority of Abu Dhabi. Going forwards we plan to increase our private-public partnerships and improve access of care to our patients.


Frederik Kier, Senior Vice President for region AAMEO

Mads Bo Larsen, Corporate Vice President at Novo Nordisk

Notify of
Inline Feedbacks
View all comments